Developer docs
API playgroundTry for free, no card

Search company profiles

Endorobotics

Full company profile

uuid0002nb7

Namestring
Endorobotics
Legal namestring
EndoRobotics Co., LTD.
Websiteurl
endorobo.com
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
endoscopic surgical robots, robotic-assisted endoscopy, minimally invasive surgery devices, gastrointestinal surgery robotics, flexible surgical robotics
Industry4 codes
PRIMARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAN
Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAB
Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAA
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Surgical Robotics / Endoscopic Surgical Robots
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Robotic Endoscopic Devices and Systems
TypeHardware Sales
Description

EndoRobotics generates revenue through the sale and distribution of robotic-assisted endoscopic technologies including the Robopera system console, articulated grippers, and scope-mounted traction devices. With the Olympus distribution partnership, the company is expanding globally into the endoscopic robotic devices market.

fiercebiotech.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1RoSE Platform
Description

World's first flexible surgical robot compatible with commercial endoscopes that can be attached to diagnostic endoscopes to transform them into surgical instruments.

endorobo.com
+4 more records
Core offering1 text field

EndoRobotics develops and manufactures robotic-assisted endoscopic surgical devices for minimally invasive gastrointestinal procedures. Its flagship Robopera system uses proprietary micro cable control technology to deliver 720-degree rotation within a 15mm throat diameter and operates as a detachable robot that transforms existing commercial diagnostic endoscopes into surgical instruments. Supporting accessories (TraCloser traction device, RollingStitch suturing instrument, EndoCubot therapeutic device) address endoscopic submucosal dissection (ESD), endoscopic sleeve gastroplasty (ESG), endoscopic mucosal resection (EMR), and endoscopic stitching procedures.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Robotic-assisted ESD procedures expected to address approximately 900,000 annual deaths from colorectal cancer globally (second leading cause of cancer deaths)
Product overview1 text field

Endorobotics develops robotic-assisted endoscopic surgical devices for minimally invasive gastrointestinal procedures. The core product is the Robopera system, a flexible surgical robot compatible with commercial endoscopes that transforms diagnostic tools into surgical instruments. Supporting products include TraCloser (traction device), RollingStitch (suturing device), and EndoCubot for various therapeutic applications. The company focuses on non-resection endoscopic procedures including Endoscopic Submucosal Dissection (ESD), Endoscopic Sleeve Gastroplasty (ESG), endoscopic stitching, and Endoscopic Mucosal Resection (EMR). EndoRobotics has established a global distribution partnership with Olympus Corporation to expand its robotic-assisted endoscopic technologies worldwide, starting with the U.S. market.

Product and service4 records
1Robopera Endoscopic Surgery Robot
CategoryEndoscopic surgical robot system
Description

FDA-cleared endoscopic surgery robot using proprietary micro cable control technology to deliver 720-degree rotation within a 15mm throat diameter. It is a detachable device that retrofits onto existing commercial diagnostic endoscopes, transforming them into surgical instruments for advanced gastrointestinal procedures such as ESD, EMR, ESG, and endoscopic stitching. Targeted at hospitals, gastroenterology departments, and endoscopists performing minimally invasive GI procedures.

2TraCloser
CategoryEndoscopic accessory / traction device
Description

Endoscopic traction device for complex therapeutic procedures, designed to enhance visualization and tissue manipulation during advanced endoscopic interventions such as ESD and EMR. Used by gastroenterologists and endoscopists performing minimally invasive GI procedures.

3RollingStitch
CategoryEndoscopic accessory / suturing device
Description

Endoscopic stitching instrument for closing defects, perforations, or incisions during procedures such as ESD or EMR. Enables suture placement through a flexible endoscope to manage complications or achieve complete closure after lesion removal. Targeted at gastroenterologists performing advanced endoscopic procedures.

4EndoCubot
CategoryEndoscopic robotic therapeutic device
Description

Endoscopic robotic device for therapeutic interventions in the gastrointestinal tract, used by endoscopists performing minimally invasive procedures.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-04
Description

Olympus signed an exclusive global distribution agreement with EndoRobotics to add robot-assisted technologies to its EndoTherapy portfolio. The partnership combines Olympus' global commercial reach with EndoRobotics' development capabilities to advance therapeutic endoscopy capabilities worldwide, beginning with the U.S. market. The collaboration aims to expand patient access to advanced endoscopic procedures like ESD for treating early-stage cancers and precancerous lesions of the GI tract.

2KIST Hongneung Science Park
Strategic tierMinorTypeOthers
Description

EndoRobotics was featured as a representative startup by KIST Hongneung Science Park at the pre-IPO PLAZA conference in the deep tech field, highlighting the company's status as a promising technology startup in South Korea's science park ecosystem.

dbr.donga.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Dominant surgical robotics incumbent behind the da Vinci platform; while focused on laparoscopic soft-tissue surgery, it is the benchmark incumbent EndoRobotics must position against as it expands robot-assisted endoscopy globally.

TypeDirect peer
Description

U.S.-based developer of a flexible robotic endoscopy system targeting upper and lower GI procedures; the closest direct competitor to EndoRobotics given overlapping flexible endoscopic robotics focus and similar indication set.

3Medicaroid
TypeDirect peer
Description

Japanese surgical robotics company (backed by Sysmex and Kawasaki Heavy Industries) behind the Hinotori system; highly comparable as an Asian-origin surgical robotics challenger pursuing global hospital accounts with a similar go-to-market profile.

TypeDirect peer
Description

U.S. company behind the Senhance surgical system, a digital laparoscopic platform targeting general surgery; comparable as a publicly-listed surgical robotics challenger working to gain share against da Vinci with a differentiated architecture.

TypeDirect peer
Description

UK-based developer of the Versius portable surgical robot for minimal-access surgery; comparable as a venture-backed soft-tissue robotics peer pursuing global commercialization with a modular design philosophy similar in spirit to EndoRobotics's detachable approach.

TypeBroad incumbent
Description

Diversified medical device giant that has launched the Hugo robotic-assisted surgery platform; broad incumbent competing across multiple specialties and capable of leveraging its installed base and capital to out-execute niche robotics challengers.

TypeBroad incumbent
Description

Owner of the MONARCH bronchoscopy robot and Ottava soft-tissue robotics platform under development; broad incumbent with the capital, clinical-trial infrastructure, and channel to compete across EndoRobotics's target indications.

TypeOthers
Description

EndoRobotics's exclusive global distribution partner and the dominant player in flexible endoscopy; listed here because Olympus is simultaneously a channel partner and a potential competitor with internal robotics programs and the Swan EndoSurgical JV.

TypeBroad incumbent
Description

Major player in GI endoscopy tools (including hemostasis, resection, and suturing devices) with growing interest in robotic endoscopy; comparable as a broad incumbent selling adjacent therapeutic accessories into the same hospital call point.

TypeEmerging player
Description

U.S. surgical robotics startup developing miniaturized robotic-assisted platforms for laparoscopic procedures; comparable as an emerging surgical robotics peer targeting similar minimally invasive indication spaces with a capital-efficient design approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Endorobotics

Surgical Robotics / Endoscopic Surgical Robotsendorobo.com

Endorobotics firmographics

Firmographics
Name
Endorobotics
Legal name
EndoRobotics Co., LTD.
Website
https://endorobo.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Endorobotics industry classification

Industry
Product category
Surgical Robotics / Endoscopic Surgical Robots
NAICS
Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAN
Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAB
Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAA
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • Endoscopic surgical robots
  • Robotic-assisted endoscopy
  • Minimally invasive surgery devices
  • Gastrointestinal surgery robotics
  • Flexible surgical robotics

Where Endorobotics is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

Endorobotics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

  1. Robotic Endoscopic Devices and Systems: EndoRobotics generates revenue through the sale and distribution of robotic-assisted endoscopic technologies including the Robopera system console, articulated grippers, and scope-mounted traction devices. With the Olympus distribution partnership, the company is expanding globally into the endoscopic robotic devices market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Endorobotics product offering

Product offering

Core offering

EndoRobotics develops and manufactures robotic-assisted endoscopic surgical devices for minimally invasive gastrointestinal procedures. Its flagship Robopera system uses proprietary micro cable control technology to deliver 720-degree rotation within a 15mm throat diameter and operates as a detachable robot that transforms existing commercial diagnostic endoscopes into surgical instruments. Supporting accessories (TraCloser traction device, RollingStitch suturing instrument, EndoCubot therapeutic device) address endoscopic submucosal dissection (ESD), endoscopic sleeve gastroplasty (ESG), endoscopic mucosal resection (EMR), and endoscopic stitching procedures.

Product overview

Endorobotics develops robotic-assisted endoscopic surgical devices for minimally invasive gastrointestinal procedures. The core product is the Robopera system, a flexible surgical robot compatible with commercial endoscopes that transforms diagnostic tools into surgical instruments. Supporting products include TraCloser (traction device), RollingStitch (suturing device), and EndoCubot for various therapeutic applications. The company focuses on non-resection endoscopic procedures including Endoscopic Submucosal Dissection (ESD), Endoscopic Sleeve Gastroplasty (ESG), endoscopic stitching, and Endoscopic Mucosal Resection (EMR). EndoRobotics has established a global distribution partnership with Olympus Corporation to expand its robotic-assisted endoscopic technologies worldwide, starting with the U.S. market.

Differentiator

Problem solved

Functional benefit

Brands

  • RoSE Platform: World's first flexible surgical robot compatible with commercial endoscopes that can be attached to diagnostic endoscopes to transform them into surgical instruments.
  • Robopera
  • TraCloser
  • RollingStitch
  • EndoCubot

Products and services

  • Robopera Endoscopic Surgery Robot FDA-cleared endoscopic surgery robot using proprietary micro cable control technology to deliver 720-degree rotation within a 15mm throat diameter. It is a detachable device that retrofits onto existing commercial diagnostic endoscopes, transforming them into surgical instruments for advanced gastrointestinal procedures such as ESD, EMR, ESG, and endoscopic stitching. Targeted at hospitals, gastroenterology departments, and endoscopists performing minimally invasive GI procedures.
  • TraCloser Endoscopic traction device for complex therapeutic procedures, designed to enhance visualization and tissue manipulation during advanced endoscopic interventions such as ESD and EMR. Used by gastroenterologists and endoscopists performing minimally invasive GI procedures.
  • RollingStitch Endoscopic stitching instrument for closing defects, perforations, or incisions during procedures such as ESD or EMR. Enables suture placement through a flexible endoscope to manage complications or achieve complete closure after lesion removal. Targeted at gastroenterologists performing advanced endoscopic procedures.
  • EndoCubot Endoscopic robotic device for therapeutic interventions in the gastrointestinal tract, used by endoscopists performing minimally invasive procedures.

Quantifiable outcome

  • Robotic-assisted ESD procedures expected to address approximately 900,000 annual deaths from colorectal cancer globally (second leading cause of cancer deaths)

Companies that use Endorobotics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Endorobotics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Endorobotics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Olympus CorporationcoreChannel Partner/ Reseller/ Distributor · 4 May 2026Olympus signed an exclusive global distribution agreement with EndoRobotics to add robot-assisted technologies to its EndoTherapy portfolio. The partnership combines Olympus' global commercial reach with EndoRobotics' development capabilities to advance therapeutic endoscopy capabilities worldwide, beginning with the U.S. market. The collaboration aims to expand patient access to advanced endoscopic procedures like ESD for treating early-stage cancers and precancerous lesions of the GI tract.
  • KIST Hongneung Science ParkminorOthersEndoRobotics was featured as a representative startup by KIST Hongneung Science Park at the pre-IPO PLAZA conference in the deep tech field, highlighting the company's status as a promising technology startup in South Korea's science park ecosystem.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Endorobotics competitors and assessment

Company assessment

Broad incumbents

  • Intuitive Surgical: Dominant surgical robotics incumbent behind the da Vinci platform; while focused on laparoscopic soft-tissue surgery, it is the benchmark incumbent EndoRobotics must position against as it expands robot-assisted endoscopy globally.
  • Medtronic: Diversified medical device giant that has launched the Hugo robotic-assisted surgery platform; broad incumbent competing across multiple specialties and capable of leveraging its installed base and capital to out-execute niche robotics challengers.
  • Johnson & Johnson MedTech: Owner of the MONARCH bronchoscopy robot and Ottava soft-tissue robotics platform under development; broad incumbent with the capital, clinical-trial infrastructure, and channel to compete across EndoRobotics's target indications.
  • Boston Scientific: Major player in GI endoscopy tools (including hemostasis, resection, and suturing devices) with growing interest in robotic endoscopy; comparable as a broad incumbent selling adjacent therapeutic accessories into the same hospital call point.

Direct peers

  • EndoQuest Robotics: U.S.-based developer of a flexible robotic endoscopy system targeting upper and lower GI procedures; the closest direct competitor to EndoRobotics given overlapping flexible endoscopic robotics focus and similar indication set.
  • Medicaroid: Japanese surgical robotics company (backed by Sysmex and Kawasaki Heavy Industries) behind the Hinotori system; highly comparable as an Asian-origin surgical robotics challenger pursuing global hospital accounts with a similar go-to-market profile.
  • Asensus Surgical: U.S. company behind the Senhance surgical system, a digital laparoscopic platform targeting general surgery; comparable as a publicly-listed surgical robotics challenger working to gain share against da Vinci with a differentiated architecture.
  • CMR Surgical: UK-based developer of the Versius portable surgical robot for minimal-access surgery; comparable as a venture-backed soft-tissue robotics peer pursuing global commercialization with a modular design philosophy similar in spirit to EndoRobotics's detachable approach.

Others

  • Olympus Corporation: EndoRobotics's exclusive global distribution partner and the dominant player in flexible endoscopy; listed here because Olympus is simultaneously a channel partner and a potential competitor with internal robotics programs and the Swan EndoSurgical JV.

Emerging players

  • Virtual Incision: U.S. surgical robotics startup developing miniaturized robotic-assisted platforms for laparoscopic procedures; comparable as an emerging surgical robotics peer targeting similar minimally invasive indication spaces with a capital-efficient design approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Endorobotics social profiles

Digital presence

Endorobotics compliance and trust

Trust signal

Compliance1 record

Endorobotics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Endorobotics leadership team

Management profile

Number of profiles

Profiles3 records

Endorobotics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Endorobotics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Endorobotics

What does Endorobotics do?

EndoRobotics develops and manufactures robotic-assisted endoscopic surgical devices for minimally invasive gastrointestinal procedures. Its flagship Robopera system uses proprietary micro cable control technology to deliver 720-degree rotation within a 15mm throat diameter and operates as a detachable robot that transforms existing commercial diagnostic endoscopes into surgical instruments. Supporting accessories (TraCloser traction device, RollingStitch suturing instrument, EndoCubot therapeutic device) address endoscopic submucosal dissection (ESD), endoscopic sleeve gastroplasty (ESG), endoscopic mucosal resection (EMR), and endoscopic stitching procedures.

Is Endorobotics a public or private company?

Endorobotics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Endorobotics founded?

Endorobotics was founded in 2016. It employs 11 to 50 people.

Where is Endorobotics based?

Endorobotics is headquartered in Seoul, South Korea, in the Asia region.

How does Endorobotics make money?

One revenue line is on record: robotic Endoscopic Devices and Systems.

Who are Endorobotics's main competitors?

Broad incumbents on record are Intuitive Surgical, Medtronic, Johnson & Johnson MedTech and Boston Scientific. Direct peers are EndoQuest Robotics, Medicaroid, Asensus Surgical and CMR Surgical. Olympus Corporation is listed as an others. Virtual Incision is listed as an emerging player.

Does Endorobotics have an API?

No public API is recorded for Endorobotics.

What industry is Endorobotics in?

Endorobotics's product category is Surgical Robotics / Endoscopic Surgical Robots. Its primary akta.pro industry code is HLAHADAF, Surgical Robotics & Computer-Assisted Surgery Platforms, with a secondary code of HLAHADAN, Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
동아사이언스Hongneung R&D Cluster Firms Target Global Market with Surgical Robots and Gene TherapiesThe Seoul Hongneung Small-scale R&D Cluster, jointly operated by KIST, Kyung Hee University, and Korea University, has produced multiple bio and medical device startups achieving global commercialization milestones. Surgical robot company Endorobotics became the first Korean medical robot maker to obtain FDA approval code NAY, the same classification as Da Vinci, and subsequently signed an exclusive global distribution agreement with Olympus while raising 32.5 billion won in Series C funding. Gene therapy company Ellisigen secured FDA expedited review designation for its AAV-based therapy and raised 42 billion won in Series C funding, while medical cannabis research company NeokenBio broke ground on a 13 billion-won GMP facility, with total cluster companies raising 754 billion won across funding rounds.Healthcare DiveOlympus’ Keith Boettiger on robotic GI surgery pushOlympus, the Tokyo-based endoscopy giant with the world's largest installed base of endoscopy systems, is expanding into robotic gastrointestinal surgery through two initiatives: co-founding Swan EndoSurgical for long-term platform development and partnering with EndoRobotics for more immediate market distribution. The company aims to address the growing global incidence of colorectal cancer, the second leading cause of cancer with nearly 900,000 deaths annually, by using robotics to democratize technically demanding endoscopic procedures like endoscopic submucosal dissection, which currently requires 200-300 procedures to achieve proficiency. Olympus continues to work with the FDA to resolve three warning letters and an import ban on some Japan-manufactured devices.Healthcare Asia MagazineJapan endoscopy market to grow 4% CAGR as robotic-assisted procedures expandJapan's endoscopy market is projected to grow at a 4% CAGR through 2036, fueled by rising gastrointestinal cancer cases and increased demand for minimally invasive procedures. Olympus has entered a global distribution agreement with South Korea's EndoRobotics to expand robotic-assisted endoscopy capabilities for complex procedures such as endoscopic submucosal dissection. An analyst noted that adoption will depend on reimbursement systems, training availability, and regulatory pathways, but ongoing innovation and industry collaborations are expected to drive broader use globally.Simply Wall StOlympus (TSE:7733) Valuation Check After New Robotics Partnerships And Surgical Product ApprovalsOlympus (TSE:7733) has signed an exclusive global distribution deal with EndoRobotics for robot-assisted EndoTherapy devices and secured two new U.S. product clearances, while also reorganizing into customer-focused divisions including Gastrointestinal Solutions and Surgical and Interventional Solutions. Despite these strategic developments, Olympus shares have declined 21.1% over the past three months and 21.3% over the past year, with the stock currently trading at ¥1,559 versus an analyst fair value estimate of ¥1,819. The article notes China policy risks and healthcare budget pressures in key markets as potential headwinds that could affect revenue and margins going forward.Simply Wall StOlympus’ Robot-Assisted GI Endoscopy Push Could Be A Game Changer For Olympus (TSE:7733)Olympus Corporation announced an exclusive global distribution agreement with EndoRobotics in early May 2026 to integrate robot-assisted endoscopic technologies into its EndoTherapy portfolio, expanding access to minimally invasive treatments for early-stage gastrointestinal cancers and precancerous lesions worldwide. The partnership combines Olympus' global commercial reach with EndoRobotics' precision tools to influence how complex GI procedures like endoscopic submucosal dissection are delivered. Analysts project this push into endoluminal robotics, alongside products like POWERSEAL and the Aplio i800 EUS launch, could support Olympus' target of ¥1108.0 billion revenue and ¥121.0 billion earnings by 2029.StartuptodayEndorobotics-Olympus, signed a global exclusive distribution agreement for endoscopic surgical robots.Endorobotics signed a global exclusive distribution agreement with Olympus for its endoscopic surgery robot, with full-scale commercialization starting in the U.S. The partnership follows Olympus's SI investment and aims to expand Endoscopic Submucosal Dissection (ESD) procedures. The deal is expected to become a milestone for domestic medical device startups.FierceBiotechOlympus, EndoRobotics in distribution pact for robot-assisted endoscopic techOlympus has entered into a global distribution agreement with South Korea's EndoRobotics for robot-assisted endoscopic technologies, aiming to leverage Olympus' commercial reach with EndoRobotics' development capabilities to advance new endotherapeutic offerings. The partnership will initially focus on the U.S. market to expand adoption of advanced endoscopic procedures including endoscopic submucosal dissection (ESD), with additional details on availability and regional launches to be announced. Tokyo-based Olympus has stated one of its goals is to expand patient access to endoscopic procedures for treating early-stage cancers and precancerous lesions of the gastrointestinal tract.Medical Device NetworkOlympus to distribute EndoRobotics’ technologies worldwideOlympus signed an exclusive global agreement to distribute EndoRobotics' robot-assisted technologies for endoscopic procedures like ESD. Initial availability starts in the US, subject to regulatory approvals. The deal aligns with Olympus's strategy to expand endoluminal robotics and therapeutic endoscopy.Mpo-magOlympus, EndoRobotics Ink Distro Deal for Robot-Assisted Endoscopy TechOlympus has signed an exclusive global distribution agreement with EndoRobotics to distribute robot-assisted endoscopy technologies worldwide as part of its EndoTherapy portfolio. The partnership aims to broaden patient access to endoscopic procedures for treating early-stage cancers and precancerous lesions of the gastrointestinal tract, with initial market rollout beginning in the United States. The collaboration supports Olympus's strategy to advance endoluminal robotics and help clinicians perform complex therapeutic procedures such as endoscopic submucosal dissection with greater precision, control, and efficiency.MedTech DiveOlympus, EndoRobotics forge distribution pactOlympus has entered into an exclusive global distribution agreement with South Korea-based EndoRobotics to market the company's endoscopic robotic devices for gastroenterology procedures, beginning in the U.S. The partnership gives Olympus access to EndoRobotics' Robopera system console, articulated grippers, scope-mounted traction device, and ESD training simulator, leveraging Olympus' commercial infrastructure to expand adoption of robot-assisted endoscopic procedures. This agreement follows Olympus' separate July partnership with Revival Healthcare Capital to co-found Swan EndoSurgical for co-developing a separate robotic platform with up to $458 million in planned joint investment.